Earnings ·
Monte Rosa reports Q3 net income of $3.1M on $54.4M collaboration revenue
GLUEMonte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics reported a third-quarter 2026 net income of $3.1 million, compared to a net loss of $27.1 million in the prior-year period. Collaboration revenue surged to $54.4 million from $12.8 million, driven by the recognition of a $50 million milestone payment triggered by Novartis initiating Phase 2 studies for MRT-6160. Operating expenses increased, with R&D at $45.4 million and G&A at $10.9 million. The company holds $582.6 million in cash and equivalents, sufficient to fund operations into 2029. Clinical updates include positive Phase 1 results for MRT-8102 and the initiation of Phase 2 studies for MRT-2359 and MRT-6160. Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader medicines.